These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1202532)

  • 21. Multiple courses of ancrod (Arvin) therapy.
    Kounis NG; Evans WH
    Br Med J; 1977 Jan; 1(6056):290-1. PubMed ID: 837082
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of severe intermittent claudication by controlled defibrination.
    Dormandy JA; Goyle KB; Reid HL
    Lancet; 1977 Mar; 1(8012):625-6. PubMed ID: 66429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hemorheological aspects of the Arvin therapy of acute thromboses of the magistral veins of the lower extremities].
    Aleksandrova NP; Leont'ev SG; Karalkin AV; Berezov VP
    Grud Serdechnososudistaia Khir; 1990 Dec; (12):15-8. PubMed ID: 2078376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Arvin in the treatment of advanced atherosclerosis. Preliminary report].
    Kroese AJ
    Tidsskr Nor Laegeforen; 1976 Apr; 96(12):700-1. PubMed ID: 936123
    [No Abstract]   [Full Text] [Related]  

  • 25. [Thrombolytic treatment of deep leg and pelvic vein thromboses].
    Breddin HK; Krzywanek HJ
    Internist (Berl); 1982 Jul; 23(7):410-6. PubMed ID: 7050003
    [No Abstract]   [Full Text] [Related]  

  • 26. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
    Glas-Greenwalt P; Kant KS; Dosekun A; Frazier J; Allen C; Pollak VE
    J Lab Clin Med; 1985 Jan; 105(1):99-107. PubMed ID: 3871465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ancrod in systemic lupus erythematosus with thrombosis. Clinical and fibrinolysis effects.
    Dosekun AK; Pollak VE; Glas-Greenwalt P; Kant KS; Penovich P; Lebron-Berges A; Weiss MA; Levinson JE
    Arch Intern Med; 1984 Jan; 144(1):37-42. PubMed ID: 6229228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Thrombolytic therapy. I. Introduction and principles of therapy. Indications. Contraindications. Schematics of the treatment].
    Sterkowicz S
    Przegl Lek; 1969; 25(8):565-8. PubMed ID: 4897431
    [No Abstract]   [Full Text] [Related]  

  • 29. Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod.
    Kant KS; Pollak VE; Dosekun A; Glas-Greenwalt P; Weiss MA; Glueck HI
    J Lab Clin Med; 1985 Jan; 105(1):77-88. PubMed ID: 3968467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arwin in peripheral arterial circulatory disorders: controlled multicentre trials.
    Wolf GK
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):387-92. PubMed ID: 786664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical and biological aspects of urokinase therapy].
    Potron G; Droulle C; Nicaise H; Seys A; Leroux B; Morice JC; Gerard J; Robert JF
    Therapie; 1975; 30(5):695-704. PubMed ID: 1221560
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hemodilution, defibrinogenation and plasmapheresis in hemorheology].
    Bartolo M
    Ric Clin Lab; 1985; 15 Suppl 1():439-54. PubMed ID: 4035226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cleavage and inactivation of plasminogen activator inhibitor type 1 and alpha2-antiplasmin by reptilase, a thrombin-like venom enzyme.
    Urano T; Ihara H; Takada Y; Fujie M; Takada A
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):145-53. PubMed ID: 10759007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulant therapy with ancrod.
    Soutar RL; Ginsberg JS
    Crit Rev Oncol Hematol; 1993 Aug; 15(1):23-33. PubMed ID: 8240705
    [No Abstract]   [Full Text] [Related]  

  • 35. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG
    Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of thrombolytic therapy in venous thromboembolic disease.
    Rubin RN
    Conn Med; 1981 Sep; 45(9):551-4. PubMed ID: 7028391
    [No Abstract]   [Full Text] [Related]  

  • 37. [Present state of heparin therapy].
    Blatrix C; Soulier JP; Vacheron A; Cornu P
    Presse Med (1893); 1969 Mar; 77(15):553-6. PubMed ID: 5796027
    [No Abstract]   [Full Text] [Related]  

  • 38. [Experience with Arvin therapy in aged patients].
    Landgraf H; Stumpf J; Knecht H; Raithel D
    Ther Ggw; 1979 Mar; 118(3):375-86. PubMed ID: 432855
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term results after defibrinogenation by Arwin in chronic occlusive arterial disease.
    Staiger J; Konrad-Graf S; Keil G
    Bibl Haematol; 1981; (47):252-7. PubMed ID: 7337665
    [No Abstract]   [Full Text] [Related]  

  • 40. Anabolic steroids and fibrinolysis.
    Lowe GD
    Wien Med Wochenschr; 1993; 143(14-15):383-5. PubMed ID: 8256452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.